SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

InnoCare Says Orelabrutinib Phase III ITP Study Met Primary Endpoint

InnoCare said its Phase III study of orelabrutinib in immune thrombocytopenia met its primary endpoint.

Related stories